NO168538C - Fremgangsmaate for fremstilling av humant leukocytt-interferon av typen ifn-alfa 2(arg) ved hjelp av mikroorganismer som koder for disse. - Google Patents

Fremgangsmaate for fremstilling av humant leukocytt-interferon av typen ifn-alfa 2(arg) ved hjelp av mikroorganismer som koder for disse.

Info

Publication number
NO168538C
NO168538C NO831903A NO831903A NO168538C NO 168538 C NO168538 C NO 168538C NO 831903 A NO831903 A NO 831903A NO 831903 A NO831903 A NO 831903A NO 168538 C NO168538 C NO 168538C
Authority
NO
Norway
Prior art keywords
interferon
leukocyty
alfa
arg
micro
Prior art date
Application number
NO831903A
Other languages
English (en)
Other versions
NO168538B (no
NO831903L (no
Inventor
Eva Dworkin-Rastl
Marc Bruce Dworkin
Guenther Adolf
Peter Meindl
Gerhard Bodo
Peter Swetly
Original Assignee
Thomae Gmbh Dr K
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6164725&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO168538(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Thomae Gmbh Dr K filed Critical Thomae Gmbh Dr K
Publication of NO831903L publication Critical patent/NO831903L/no
Publication of NO168538B publication Critical patent/NO168538B/no
Publication of NO168538C publication Critical patent/NO168538C/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1096—Processes for the isolation, preparation or purification of DNA or RNA cDNA Synthesis; Subtracted cDNA library construction, e.g. RT, RT-PCR
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/14—Lymphokine; related peptides
    • Y10S930/142—Interferon

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
NO831903A 1982-05-28 1983-05-27 Fremgangsmaate for fremstilling av humant leukocytt-interferon av typen ifn-alfa 2(arg) ved hjelp av mikroorganismer som koder for disse. NO168538C (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19823220116 DE3220116A1 (de) 1982-05-28 1982-05-28 Mikrobiologisch hergestellte (alpha)- und ss-interferone, dna-sequenzen, die fuer diese interferone codieren, mikroorganismen, die diese genetische information enthalten, und verfahren zu ihrer herstellung

Publications (3)

Publication Number Publication Date
NO831903L NO831903L (no) 1983-11-29
NO168538B NO168538B (no) 1991-11-25
NO168538C true NO168538C (no) 1992-03-04

Family

ID=6164725

Family Applications (1)

Application Number Title Priority Date Filing Date
NO831903A NO168538C (no) 1982-05-28 1983-05-27 Fremgangsmaate for fremstilling av humant leukocytt-interferon av typen ifn-alfa 2(arg) ved hjelp av mikroorganismer som koder for disse.

Country Status (22)

Country Link
US (1) US4820638A (no)
EP (1) EP0095702B1 (no)
JP (2) JPH0774238B2 (no)
KR (1) KR920006349B1 (no)
AT (1) ATE42114T1 (no)
AU (1) AU565479B2 (no)
DD (1) DD211359C4 (no)
DE (2) DE3220116A1 (no)
DK (1) DK164742C (no)
ES (2) ES8403522A1 (no)
FI (1) FI82072C (no)
GR (1) GR79236B (no)
HK (1) HK112893A (no)
HU (1) HU196452B (no)
IL (1) IL68790A (no)
MX (1) MX9202815A (no)
NO (1) NO168538C (no)
NZ (1) NZ204384A (no)
SG (1) SG38692G (no)
SU (1) SU1346048A3 (no)
UA (1) UA8037A1 (no)
ZA (1) ZA833845B (no)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3247922A1 (de) * 1982-12-24 1984-06-28 Boehringer Ingelheim International GmbH, 6507 Ingelheim Dna-sequenzen, deren herstellung, diese sequenzen enthaltende plasmide und deren verwendung zur synthese eukaryotischer genprodukte in prokaryoten
DE3515336C2 (de) * 1985-04-27 1994-01-20 Boehringer Ingelheim Int Verfahren zur Herstellung und Reinigung von â-Interferon
US4709324A (en) * 1985-11-27 1987-11-24 Motorola, Inc. Data processor control unit having an interrupt service using instruction prefetch redirection
CA2025180A1 (en) * 1989-10-12 1991-04-13 William G. Weisburg Nucleic acid probes and methods for detecting pathogenic candida yeasts
US6685933B1 (en) 1998-07-28 2004-02-03 The United States Of America As Represented By The Department Of Health And Human Services Interferon α hybrids
BR0115392A (pt) * 2000-11-03 2004-06-15 Biomedicines Inc Método para o tratamento de uma doença sensìvel a interferona em um animal de sangue quente, método para individualizar as dosagens de uma interferona no tratamento, método para a fabricação de um dispositivo de liberação de efeito terapêutico de longa duração de uma droga ao longo de um perìodo de tempo, e conjunto útil para a ministração de uma quantidade relativamente constante de uma droga
FR2817559B1 (fr) * 2000-12-06 2003-12-12 Genodyssee Procede de determination d'un ou plusieurs polymorphisme(s) fontionnel(s) dans la sequence nucleique d'un gene "candidat" fonctionnel preselectionne et ses applications
FR2821625B1 (fr) * 2001-03-01 2003-05-16 Genodyssee Nouveaux polynucleotides comportant un polymorphisme de type snp fonctionnel dans la sequence nucleotidique du gene ifn-alpha-2 ainsi que de nouveaux polypeptides codes par ces polynucleotides et leurs utilisations therapeutiques
FR2823220B1 (fr) * 2001-04-04 2003-12-12 Genodyssee Nouveaux polynucleotides et polypeptides de l'erythropoietine (epo)
CN100438870C (zh) * 2001-11-09 2008-12-03 精达制药公司 ω干扰素在制备治疗温血动物对象中病毒性疾病的药物中的用途
US20040063912A1 (en) * 2002-03-15 2004-04-01 The Brigham And Women's Hospital, Inc. Central airway administration for systemic delivery of therapeutics
WO2003099320A1 (en) 2002-05-24 2003-12-04 Zensun (Shanghai) Sci-Tech.Ltd Neuregulin based methods and compositions for treating viral myocarditis and dilated cardiomyopathy
CA2498319A1 (en) * 2002-09-09 2004-03-18 Nautilus Biotech Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules
WO2005074650A2 (en) 2004-02-02 2005-08-18 Ambrx, Inc. Modified human four helical bundle polypeptides and their uses
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
EP2020990B1 (en) 2006-05-30 2010-09-22 Intarcia Therapeutics, Inc Two-piece, internal-channel osmotic delivery system flow modulator
AU2007284759B2 (en) 2006-08-09 2010-10-28 Intarcia Therapeutics, Inc. Osmotic delivery systems and piston assemblies
US20080260820A1 (en) * 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides
AU2008244523B2 (en) 2007-04-23 2012-02-16 Intarcia Therapeutics, Inc. Suspension formulations of insulinotropic peptides and uses thereof
EP2240155B1 (en) 2008-02-13 2012-06-06 Intarcia Therapeutics, Inc Devices, formulations, and methods for delivery of multiple beneficial agents
RU2547990C2 (ru) 2009-09-28 2015-04-10 Интарсия Терапьютикс, Инк. Быстрое достижение и/или прекращение существенной стабильной доставки лекарственного средства
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
WO2013024158A1 (en) 2011-08-17 2013-02-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Combinations of protein kinase inhibitors and interferons or of protein kinase inhibitors and direct acting antivirals for the treatment and the prevention of hcv infection
WO2013024156A2 (en) 2011-08-17 2013-02-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Combinations of anti-hcv-entry factor antibodies and interferons for the treatment and the prevention of hcv infection
WO2014033266A1 (en) 2012-08-31 2014-03-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-sr-bi antibodies for the inhibition of hepatitis c virus infection
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
EP3302354B1 (en) 2015-06-03 2023-10-04 i2o Therapeutics, Inc. Implant placement systems
RU2760007C2 (ru) 2016-05-16 2021-11-22 Интарсия Терапьютикс, Инк. Полипептиды, селективные к рецепторам глюкагона, и способы их применения
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
WO2018129058A1 (en) 2017-01-03 2018-07-12 Intarcia Therapeutics, Inc. Methods comprising continuous administration of a glp-1 receptor agonist and co-adminstration of a drug

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2906160A1 (de) * 1979-02-17 1980-09-04 Thomae Gmbh Dr K Verbessertes verfahren zur herstellung von humaninterferon
AU538665B2 (en) * 1979-10-30 1984-08-23 Juridical Foundation, Japanese Foundation For Cancer Research Human interferon dna
IL58765A (en) * 1979-11-21 1986-09-30 Yeda Res & Dev Process for the production of essentially pure messenger rna of human fibroblast interferon and process for the production of interferon beta
US4530901A (en) * 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
IE54096B1 (en) * 1980-01-08 1989-06-21 Biogen Nv Dn sequences, recombinant dna molecules and processes for producing human interferon - like polypeptides
GB2068970B (en) * 1980-02-06 1983-06-22 Searle & Co Recombinant dna technique for the preparation of a protein resembling human interferon
DE3005897A1 (de) * 1980-02-16 1981-09-03 Hoechst Ag, 6000 Frankfurt Genprodukt eines hoeheren organismus aus einem dieses gen enhtaltenden mikroorganismus
DE3005843A1 (de) * 1980-02-16 1981-09-10 Hoechst Ag, 6000 Frankfurt Genprodukt eines hoeheren organismus aus einem dieses gen enthaltenden mikroorganismus
ES506955A0 (es) * 1980-11-10 1983-02-01 Genentech Inc Un procedimiento para producir un polipeptido antiviral.
DE3106982A1 (de) * 1981-02-25 1982-09-09 Dr. Karl Thomae Gmbh, 7950 Biberach "neues tridecadeoxynukleotid, verfahren zu seiner herstellung und verwendung"
IL63327A (en) * 1981-07-16 1985-11-29 Yeda Res & Dev Production of interferon beta1 and alpha-phage recombinants for its production in host bacteria
GB2108510B (en) 1981-10-03 1984-12-12 Ciba Geigy Ag Dnas, recombinant dnas, hosts containing them, polypeptides and processes for the production thereof

Also Published As

Publication number Publication date
DK239383A (da) 1983-11-29
FI82072C (fi) 1991-01-10
ES522762A0 (es) 1984-03-16
DK164742B (da) 1992-08-10
NZ204384A (en) 1986-11-12
IL68790A (en) 1991-06-10
ES8500321A1 (es) 1984-10-01
JPH0774238B2 (ja) 1995-08-09
EP0095702A1 (de) 1983-12-07
KR920006349B1 (ko) 1992-08-03
FI82072B (fi) 1990-09-28
DE3379591D1 (en) 1989-05-18
MX9202815A (es) 1992-06-30
SG38692G (en) 1992-09-04
DE3220116A1 (de) 1983-12-01
FI831818L (fi) 1983-11-29
DK239383D0 (da) 1983-05-27
IL68790A0 (en) 1983-09-30
HU196452B (en) 1988-11-28
FI831818A0 (fi) 1983-05-23
ATE42114T1 (de) 1989-04-15
HK112893A (en) 1993-10-29
AU1504483A (en) 1983-12-01
AU565479B2 (en) 1987-09-17
DE3220116C2 (no) 1993-02-18
ES529360A0 (es) 1984-10-01
DD211359A5 (de) 1984-07-11
JPS5925689A (ja) 1984-02-09
NO168538B (no) 1991-11-25
ES8403522A1 (es) 1984-03-16
UA8037A1 (uk) 1995-12-26
DK164742C (da) 1992-12-28
ZA833845B (en) 1985-01-30
JPH0678774A (ja) 1994-03-22
DD211359C4 (de) 1986-09-24
NO831903L (no) 1983-11-29
JP2558422B2 (ja) 1996-11-27
SU1346048A3 (ru) 1987-10-15
US4820638A (en) 1989-04-11
KR840004944A (ko) 1984-10-31
GR79236B (no) 1984-10-22
EP0095702B1 (de) 1989-04-12

Similar Documents

Publication Publication Date Title
NO168538C (no) Fremgangsmaate for fremstilling av humant leukocytt-interferon av typen ifn-alfa 2(arg) ved hjelp av mikroorganismer som koder for disse.
AU5554986A (en) Treatment of viral diseases with azolylmethyloxiranes
LU88327I2 (fr) Interferon gamma-1b (Imukin /Immukine)
DE3770915D1 (de) Menschliches apolipoprotein a1 sowie dessen variante, exprimiert in escherichia coli.
ATE91722T1 (de) Pferde-gamma-interferon.
IL80562A0 (en) Recombinant human lysozyme,its preparation by recombinant dna technology and pharmaceutical compositions containing it
DE58908428D1 (de) Sekretormutante von Escherichia coli.
DE3881023D1 (de) Proteine, expressionsvektoren, die fuer solche proteine kodierende dna enthalten und zellen, die solche expressionsvektoren enthalten.
EP0188262A3 (en) Process for the isolation of chicken egg white cystatine, antiviral agents containing it and its use as viral protease inhibitor
GB8414354D0 (en) Purifying protein
AU570572B2 (en) 4,5-dihydro-4-oxo-2-((2-trans-phenylcyclopropyl) amino)-3- furancarboxylic acid derivatives
EP0490383A3 (en) Peptides of the hiv-gag protein, their preparation and use
DE69306273T2 (de) Mitogen für die glatte Muskulatur und dessen kodierende DNS
AU560165B2 (en) Chromophoric peptides
JPS5775960A (en) Purified polypeptide
NO882836L (no) Fremgangsmaate for kjemisk modifisering av protider (proteiner og peptider).
DK547486A (da) Peptider samt praeparater indeholdende disse